Modality
Cell Therapy
MOA
PD-L1i
Target
FXIa
Pathway
JAK/STAT
DLBCL
Development Pipeline
Preclinical
Oct 2020
→ Jun 2031
PreclinicalCurrent
NCT05148814
147 pts·DLBCL
2020-10→2031-06·Completed
147 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-065.2y awayInterim· DLBCL
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Preclinical
Complet…
Catalysts
Interim
2031-06-06 · 5.2y away
DLBCL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05148814 | Preclinical | DLBCL | Completed | 147 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa |